Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of Trontinemab (RO7126209) in healthy volunteers
NCT04023994Phase 1Completed
- Sponsor
- Roche
- Start
- Aug 2019
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of trontinemab in Alzheimer's disease (AD) (6 arms), sponsored by Roche. Primary endpoint: Percentage of Participants With Adverse Events (AEs) up to 9 weeks. Started Aug 2019; status: completed.
02
Drugs
trontinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04023994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04023994.